NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: SCHOTT North America
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth - SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy - SCHOTT.com
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth

 

NewswireToday - /newswire/ - Mainz, Rhineland-Palatinate, Germany, 2022/08/01 - SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy - SCHOTT.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• SCHOTT Pharma AG & Co. KGaA optimally positioned to further pursue its sustainable growth strategy;
• Pharma drug containment and system solutions business successfully developed over many years;
• Capital market readiness envisaged.

As a pioneer in pharma drug containment and system solutions, the international technology group’s pharma division has grown faster than the market in recent years. As part of the carve-out, the pharma business will operate under the new name SCHOTT Pharma AG & Co. KGaA as of today. "By creating a separate legal entity for our pharma business, we are generating new opportunities to expedite our profitable growth," says SCHOTT CEO Dr. Frank Heinricht. "At the same time, this step enables us to explore new financing options, including a possible IPO for SCHOTT Pharma," adds CFO Dr. Jens Schulte.

"Pharma will remain an integral part of SCHOTT in the future. With this move, we are creating more room for organic and inorganic growth and further potential investments towards becoming climate neutral by 2030," Heinricht continues.

Pharma drug containment and system solutions, just as drug manufacturing, is subject to the strictest regulations. Working in a dynamic market with high barriers to entry, SCHOTT Pharma is optimally positioned to develop new opportunities. The portfolio ranges from high-quality vials to glass and polymer syringes to cartridges and ampoules. The company produces around 13 billion products yearly to serve modern drug categories such as mRNA-based drugs and biopharmaceuticals. Approximately every minute, over 25,000 people around the world receive an injection with medication filled in a SCHOTT Pharma product.

"In recent years, our sales in the pharma division have increased continuously, with the latest figure growing double-digit to EUR 650 million for the 2021 fiscal year although the share of sales related to COVID-19 was only about 3%," says Schulte. The company is investing a three-digit million Euro figure to meet worldwide demand. A new production facility for prefillable polymer syringes has started operations in Germany, and a new plant for glass syringes is currently under construction in Hungary. The company broke ground on new production buildings in China and is planning to triple its capacity for high-quality sterile vials in the USA. As of today, the SCHOTT Group’s pharma division is operating as a stand-alone company, however, the carve-out is expected be completed by the end of year.

SCHOTT Pharma at a glance

Special container solutions are needed to ensure vital medications reach people safely - which is exactly what SCHOTT (schott.com) has been specializing in for over 100 years. Every day, a team of around 4,800 people from over 65 nations work at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. Currently, SCHOTT Pharma has over 1,700 customers including the top 30 leading pharma manufacturers. With over 900 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. As a company of the Carl Zeiss Foundation, SCHOTT Group and its subsidiaries are committed to sustainable development for society and the environment. In light of this spirit, SCHOTT Pharma has committed to becoming climate-neutral by 2030.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SCHOTT North America

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rina Della Vecchia - SCHOTT North America, Inc. 
914-831-2286 rina.dellavecchia[.]us.schott.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SCHOTT North America securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SCHOTT North America / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)